Lin28 1632

Confirm delete?

Lin28 1632

Zoom

Cat No: 22401

Biochemicals - More Biochemicals

Lin28 1632 is a small molecule inhibitor of the interaction between the RNA binding protein Lin28 and let-7 precursor RNA (IC50 = 8 μM in a competition ELISA).{41072} It increases levels of endogenous let-7 miRNAs and decreases Lin28 expression in a d...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

N-methyl-N-[3-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]-acetamide

Correlated keywords:

Lin281632 Lin 28 281632 PC-3 DU-145 Huh-7 mi-RNA m-ESC 22-Rv1 let7 m-ESCs 22Rv-1 PC-3 DU-145 22-Rv1 BRD-4

Product Overview:
Lin28 1632 is a small molecule inhibitor of the interaction between the RNA binding protein Lin28 and let-7 precursor RNA (IC50 = 8 μM in a competition ELISA).{41072} It increases levels of endogenous let-7 miRNAs and decreases Lin28 expression in a dose-dependent manner in murine embryonic stem cells (mESCs). Lin28 1632 inhibits clonogenic growth of 22Rv1, PC3, DU145, and Huh7 cancer cells and decreases tumor-sphere formation by 22Rv1 and Huh7 cells in vitro. It also binds bromodomain-containing protein 4 (BRD4) and CREB-binding protein (CBP/CREBBP) bromodomains (Kds = 7 and 25 μM, respectively).

Size	1 mg
Shipping	dry ice
CAS Number	108825-65-6
Molecular Formula	C₁₅H₁₅N₅O
SMILES	CN(C(C)=O)C1=CC=CC(C(C=C2)=NN3C2=NN=C3C)=C1
Molecular Weight	281,3
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2924.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.